Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

The head of German pharmaceutical company BioNTech said Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming year.
Ugur Sahin, the chief executive of BioNTech, rejected the US-backed proposal to temporarily lift some intellectual property rights for vaccines.
In a call with investors announcing the company's first-quarter net profit of USD 1.37 billion, Sahin said BioNTech and its US partner Pfizer had already delivered vaccines to more than 90 countries and more than doubled its forecast production capacity for the year.

Vaccine maker BioNTech says no need to waive patents

Covid-19 vaccine-patent debate heats up
BioNTech rejects US call to waive vaccine patents
BioNTech: can produce enough shots to supply the world
Last week,&nbsp;Biden administration endorsed waiver proposal
Wavier to help vaccine production for lower-income nations

The head of German pharmaceutical company BioNTech said Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming year.
Ugur Sahin, the chief executive of BioNTech, rejected the US-backed proposal to temporarily lift some intellectual property rights for vaccines.
In a call with investors announcing the company's first-quarter net profit of USD 1.37 billion, Sahin said BioNTech and its US partner Pfizer had already delivered vaccines to more than 90 countries and more than doubled its forecast production capacity for the year.

Pfizer, BioNTech propose to expand Phase-3 trials for Covid vaccine

Pharma giants Pfizer and BioNtech&nbsp;have urged the US&nbsp;Food and Drug administration department to allow them to expand the Covid-19 vaccine trials.
The 2 companies have suggested to take forward the Phase 3 trials on as many as 40,000 individuals with diverse backgrounds to collect more safety and efficacy data.&nbsp;Currently, both companies in their joint statement claimed&nbsp;that they will complete the trial on 30,000 individuals by next week.
The proposed expansion, if approved, will allow the companies to carry out trials on people as young as 16 and on&nbsp;people with&nbsp;HIV, Hepatitis C, and Hepatitis B.
Meanwhile, both companies&nbsp;are likely to be among the first in the US to report efficacy data from Phase 3 trials; they are expecting a conclusive readout on the efficacy of the vaccine candidate&nbsp;by the end of October.&nbsp;

Pfizer, BioNTech propose to expand Phase-3 trials

Pfizer, BioNTech propose to expand Phase-3 trials USFDA&nbsp;yet to approve expansion proposal for trial Companies&nbsp;want to do trials on 44,000 individuals Individuals from diverse backgrounds to be used Trials to be carried&nbsp;out on young and ailing people

Pharma giants Pfizer and BioNtech&nbsp;have urged the US&nbsp;Food and Drug administration department to allow them to expand the Covid-19 vaccine trials.
The 2 companies have suggested to take forward the Phase 3 trials on as many as 44,000 individuals with diverse backgrounds to collect more safety and efficacy data.&nbsp;Currently, both companies in their joint statement claimed&nbsp;that they will complete the trial on 30,000 individuals by next week.
The proposed expansion, if approved, will allow the companies to carry out trials on people as young as 16 and on&nbsp;people with&nbsp;HIV, Hepatitis C, and Hepatitis B.
Meanwhile, both companies&nbsp;are likely to be among the first in the US to report efficacy data from Phase 3 trials; they are expecting a conclusive readout on the efficacy of the vaccine candidate&nbsp;by the end of October.&nbsp;

biontech

Categories